Rami Mortada, MD
Endocrinology, Diabetes & Metabolism · Wichita, KSNPI 1174720205
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,079 of the $105,366 with a category attached, or 76.9%. Novo Nordisk accounts for 86.9% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2019 at $42,783 and has fallen 93.8% since, to $2,634 in 2025. Among endocrinology, diabetes & metabolism clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,135 payments — averaging $92.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$92K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- Amgen$1K
- AstraZeneca$1K
- Abbott$873
- plus $7K from 47 others
What the payments were for
- Speaking & faculty fees$81,07977%
- Travel & lodging$6,5206%
- Food & beverage$17,50517%
- Education$2620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,366 in reported general payments places this provider in the 90th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 286 | $341,971 |
| TrulicityDulaglutide | 152 | $165,199 |
| JardianceEmpagliflozin | 174 | $150,553 |
| MounjaroTirzepatide | 78 | $92,325 |
| GenotropinSomatropin | 44 | $90,541 |
| FarxigaDapagliflozin Propanediol | 89 | $82,033 |
| Tresiba Flextouch U-200Insulin Degludec | 75 | $76,826 |
| Tresiba Flextouch U-100Insulin Degludec | 122 | $71,070 |
| ProliaDenosumab | 33 | $57,024 |
| TymlosAbaloparatide | 15 | $44,619 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 50 | $40,126 |
| JanuviaSitagliptin Phosphate | 64 | $39,938 |
| OmnitropeSomatropin | 19 | $35,415 |
| Teriparatide | 15 | $34,045 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $31,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $91,549 | $375,121356 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $2,467 | $261,931264 claims |
| Boehringer IngelheimJardiance, Tradjenta | $658 | $159,650192 claims |
| PfizerGenotropin | $227 | $90,54144 claims |
| AstraZenecaFarxiga | $1,021 | $82,03389 claims |
| AmgenProlia | $1,053 | $57,02433 claims |
| MerckJanuvia, Janumet Xr | $79 | $51,80386 claims |
| Radius Health, Inc.Tymlos | $108 | $44,61915 claims |
| Alvogen IncTeriparatide | $13 | $34,04515 claims |
| AbbVieSynthroid | $610 | $29,188307 claims |
| Johnson & JohnsonInvokana | $64 | $10,66913 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $338 | $9,1281,118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Wichita
- Dany ZayourWichita$744K
- Georges ElhomsyWichita$14K
- Sahar HachemWichita$5K
- Youssef HassanWichita$2K
- Ali JamalallailWichita$2K
- Syeda BatoolWichita$156
- Lillian HarstineWichita$12
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Sajeev MenonOverland Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.